This photo taken on March 31, 2025 shows the exhibition booth of Invest in China at Hannover Messe 2025 in Hannover, Germany.

HANNOVER, Germany, April 4 (Xinhua) -- Jochen Koeckler, Chairman of the Managing Board of Deutsche Messe AG, the organizer of Germany's Hannover Messe, said that Chinese products and solutions are ...

Chinese industrial companies’ profits declined at the start of the year but showed signs of improvement, suggesting that Beijing’s stimulus is having some effect. Industrial profits fell 0.3% ...

The second edition of The Asia Manufacturing Index by Dezan Shira & Associates is now out. The 2025 index provides essential insights into Asia’s dynamic industrial landscape, ranking eleven countries ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk of adverse cardiovascular outcomes. Merck is fronting $200 million to ...

NEW YORK – Merck on Tuesday said it has licensed an investigational lipoprotein(a) inhibitor and cardiovascular medication developed by Jiangsu Hengrui Pharmaceuticals. Merck will pay Hengrui Pharma ...